



## Yondelis® (trabectedin) – New warning

- On May 18, 2017, the FDA approved an update to the *Warnings and Precautions* section of the [Yondelis \(trabectedin\)](#) drug label, regarding capillary leak syndrome (CLS).
- Yondelis is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
- CLS characterized by hypotension, edema, and hypoalbuminemia has been reported with Yondelis, including serious CLS resulting in death.
  - Patients should be monitored for signs and symptoms of CLS.
  - If CLS is present, Yondelis should be discontinued and standard management for patients with CLS, which may include a need for intensive care, should be promptly initiated.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.